Journal of Bone and Mineral Metabolism

, Volume 15, Issue 3, pp 153–159

Clinical application of immunoassay for urinary total excretion of deoxypyridinoline in patients with osteoporosis

Authors

  • Kiyoshi Nakatsuka
    • Geriatric Medicine and Second Department of Internal MedicineOsaka City University Medical School
  • Takami Miki
    • Geriatric Medicine and Second Department of Internal MedicineOsaka City University Medical School
  • Kiichiro Sekiya
    • Geriatric Medicine and Second Department of Internal MedicineOsaka City University Medical School
  • Hidetaka Kawakami
    • Geriatric Medicine and Second Department of Internal MedicineOsaka City University Medical School
  • Yoshiko Hirota
    • Research and Development DepartmentMitsubishi Kagaku Bio-Clinical Laboratories
  • Masakazu Miura
    • Research and Development DepartmentMitsubishi Kagaku Bio-Clinical Laboratories
  • Yasue Obi
    • Gynecology, Obi Clinic
  • Yoshiki Nishizawa
    • Geriatric Medicine and Second Department of Internal MedicineOsaka City University Medical School
  • Hirotoshi Morii
    • Geriatric Medicine and Second Department of Internal MedicineOsaka City University Medical School
Original Articles

DOI: 10.1007/BF02489948

Cite this article as:
Nakatsuka, K., Miki, T., Sekiya, K. et al. J Bone Miner Metab (1997) 15: 153. doi:10.1007/BF02489948

Abstract

Urinary excretion of pyridinium cross-links is one of the biochemical markers for bone resorption in metabolic bone diseases. Efficacy of immunoassay for deoxypyridinoline (D-pyr) for monitoring effects of antiresorptive therapy was evaluated in 44 women with osteoporosis, including 4 patients with asymptomatic primary hyperparathyroidism. Urinary free forms and protein-bound (conjugated) forms of D-pyr were measured totally by a modified enzyme-liked immunoabsorbent assay (ELISA; PYRILINKS-DTM, Metra Biosystem, Mountain View, CA, USA), which required prehydrolysis of urine samples and adequate acidity adjusted with alkali. There was a close relationship between total excretion of D-pyr measured by reverse-phase high performance liquid chromatography (HPLC) and that measured by ELISA. In 27 patients, the percent change of urinary D-pyr by ELISA following hormone replacement therapy (HRT) was similar to that of urinary total forms of D-pyr using HPLC at the end of the first third, and sixth month. In 8 patients whose series of urine samples were corrected following HRT, the percent change of urinary total excretion of D-pyr by ELISA at the end of the third month was approximately −40%, significantly greater than that of excretion of free forms of D-pyr measured by ELISA (−30%;P<.01). In 16 patients, total urinary D-pyr excretion measured by both methods of HPLC and ELISA decreased by approximately 12% within 4h after a single administration of 20 IU of salmon calcitonin. There were significant differences between percent change of urinary total excretion and that of free forms of D-pyr measured by ELISA (P<.05). We conclude that short-term and subtle change of bone resorption following a single injection of salmon calcitonin, as well as long-term effects of HRT, can be detected by measuring total D-pyr excretion in urine irrespective of assays utilized. A modified assay using ELISA for urinary total D-pyr with an easy procedure provides an informative and cost-beneficial tool in monitoring bone resorption in patients with osteoporosis.

Key words

pyridinium cross-linkimmunoassayosteoporosishormone replacement therapycalcitonin
Download to read the full article text

Copyright information

© Springer-Verlag 1997